WINNIPEG, MANITOBA -- (MARKET WIRE) -- April 20, 2007 -- Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular drug discovery and development company, today announced that AGGRASTAT® (tirofiban), indicated for the treatment of acute coronary syndrome, is the focus of an article titled, “Current strategies with high-dose tirofiban”, in the April edition of the peer reviewed journal Expert Opinion on Drug Metabolism & Toxicology. The article’s lead authors are Dr. Debabrata Mukherjee, from the Gill Heart Institute at the University of Kentucky and Dr. Marco Roffi, from the Division of Cardiology, University Hospital, Zurich, Switzerland. Medicure acquired the exclusive U.S. rights to AGGRASTAT®, in August 2006.
